Orchard Therapeutics plc (NASDAQ: ORTX) shares are -53.09% down in the year-to-date (YTD) period and have moved 18.57% or $1.01 higher in the latest trading session. However, stock’s trailing 12-month performance remains nearly +45.27% lower. Comparatively, the stock is -59.51% down YTD and -30.57% over the trailing 3-month period. If we look at the shorter duration, its week performance is 38.41% and 30.30% over the month.
On September 17, 2019, Guggenheim recommended the ORTX stock is a Buy, while earlier, Oppenheimer had Resumed the stock as a Outperform on June 01, 2020. 7 analysts offering the recommendations for the stock have a consensus rating of 1.60 to suggest that the ORTX stock is a “Strong Buy. 0 of the 7 analysts rate the stock as a “Sell”, while 0 has rated it as “Underweight”. 7 recommend buying, with 0 rating it as an Overweight.
The stock currently trades at $6.45. The forecasts give the Orchard Therapeutics plc stock a price target range of $26.00 on the higher side while at least one analyst think the stock could plunge to a low of $9.00. The two limits represent an upside potential of 75.19% or 28.33%.
Analysts estimate the earnings to decrease -14.30% in the current quarter to -$0.45, down from the -$0.38 reported in the same quarter a year ago. For the current year, earnings should grow to an average of -$1.88, down -52.60% from -$1.75 reported last year. Analysts also offered guidance for the next financial quarter, with their average projected EPS at between -$0.53 and -$0.35. Wall Street estimates earnings per share to be at an average of -$1.78 for the next year.
Insider Transactions Summary
FMR LLC, a See Remark 1 at the company, sold 19,721 shares worth $0.27 million at $13.49 per share on Jan 02. The insider had earlier sold another 4,921 ORTX shares valued at $63973.0 on Mar 02. The shares were sold at $13.00 per share.
Pareteum Corporation (NASDAQ:TEUM), on the other hand, is trading around $0.68 with a market cap of $94.80M and analyst research firms have a positive stance on its shares. Some analysts are even forecasting $0 per share in earnings this year on a short term (1 year) basis.
Let us briefly look at the Pareteum Corporation (TEUM) financials, with a focus on its operating details as indicated in its earnings report for the last quarter.
Company balance sheet and cash flow
TEUM’s operating expenses over the recent quarter were at $18.99 million. This represented a 44.39% of the company’s total revenues which amounted $34.15 million. With this in place, we can see that the company’s diluted EPS declined $0.00 on the year-over-year period, growing to $0.03 as given in the last earnings report.
In terms of the balance sheet & cash flow as of (Sep 2019), the total assets figure advanced to $246.87 million from $236.95 million over the previous quarter. The cash flow from operating activities totaled -$10.44 million, significantly lower than the -$0.95 million reported in the year-ago quarter. The company’s free cash flow for the quarter was -$12.09 million.
Insiders have transacted a total of 5 times at Pareteum Corporation over the last 6 months, with insider purchases undertaken 5 times and accounting for 1,151,800 shares. Insider sales totaled 0 shares over the same period, with these deals completed in 0 transactions. Looking at these numbers, we realize that net purchases over that period are 5.0 shares. Insiders now hold a total of 6.63M shares after the latest sales, with 56.00% net shares purchased.
Insiders own 5.93% of the company shares, while shares held by institutions stand at 33.35% with a share float percentage of 103.28M. Investors are also buoyed by the number of investors in a company, with Pareteum Corporation having a total of 93 institutions that hold shares in the company.